J&J (JNJ) Considering $20B Bid for Switzerland's Synthes
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Join SI Premium – FREE
According to reports from the WSJ over the weekend, Johnson & Johnson (NYSE: JNJ) could be looking to make a $20 billion offer for Switzerland's Synthes, one of the top competitors in the market for orthopedic devices.
Such a purchase would mark Johnson & Johnson's largest-ever acquisition and give the company a foothold in the $5.5 billion trauma market.
Synthes manufactures and distributes instruments, implants and biomaterials for the surgical fixation and regeneration of human skeleton and its soft tissues, and products for operative treatment of bone fractures.
While the situation is fluid and "fragile" according to one source, market players have already brought up possible regulatory scrutiny as a deal could have a combined company controlling more than half of the trauma market.
Shares of J&J are flat at $60.56.
Such a purchase would mark Johnson & Johnson's largest-ever acquisition and give the company a foothold in the $5.5 billion trauma market.
Synthes manufactures and distributes instruments, implants and biomaterials for the surgical fixation and regeneration of human skeleton and its soft tissues, and products for operative treatment of bone fractures.
While the situation is fluid and "fragile" according to one source, market players have already brought up possible regulatory scrutiny as a deal could have a combined company controlling more than half of the trauma market.
Shares of J&J are flat at $60.56.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Mavis acquires Pep Boys from Icahn Enterprises for $700M
- U.S. Gold Corp. forms special committee to assess M&A interest
Create E-mail Alert Related Categories
Mergers and Acquisitions, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
